Lexicon Pharmaceuticals will host a virtual webcast on LX9211 for diabetic peripheral neuropathic pain on January 28, 2025.
Quiver AI Summary
Lexicon Pharmaceuticals, Inc. announced it will host a virtual webcast titled “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain” on January 28, 2025, from 9:00 a.m. to 11:00 a.m. ET, ahead of expected topline data from the Phase 2b PROGRESS trial. The event will focus on LX9211's potential for treating diabetic peripheral neuropathic pain (DPNP) and will feature presentations from key company leaders, including CEO Mike Exton and CMO Craig Granowitz. Additionally, there will be an expert panel discussion with medical professionals specializing in diabetes, including Dr. Rodica Pop-Busui and Dr. Steve Edelman. The event will be accessible through the Lexicon website, and a recording will be available afterward. Lexicon Pharmaceuticals is dedicated to developing innovative therapies through its extensive genomics research.
Potential Positives
- The announcement of a virtual webcast for LX9211 demonstrates the company's proactive approach in engaging with the medical community and stakeholders, highlighting their commitment to transparency and collaboration.
- The upcoming presentation of topline data from the Phase 2b PROGRESS trial anticipates vital data that could potentially influence the future development and market positioning of LX9211 in treating diabetic peripheral neuropathic pain (DPNP).
- Inclusion of an expert panel featuring prominent figures in the diabetes and endocrinology fields may enhance credibility and interest in Lexicon's research and development efforts.
Potential Negatives
- The announcement of a virtual webcast instead of a physical event may indicate a lack of confidence in the progress of their clinical trials or the need for a more controlled environment for updates.
- The timing of the webcast just before the anticipated topline data release from the Phase 2b PROGRESS trial could imply a level of urgency or pressure on the company to address stakeholder concerns regarding trial outcomes.
- The reliance on expert opinions and Q&A sessions during the webcast may suggest that the company feels it is necessary to bolster its credibility and reassure investors in light of potential uncertainties concerning its drug development efforts.
FAQ
What is the date and time of the LX9211 webcast?
The LX9211 webcast is scheduled for January 28, 2025, from 9:00 a.m. to 11:00 a.m. ET.
How can I register for the LX9211 virtual event?
You can register for the event by visiting the Events section on the Lexicon website.
What will be discussed during the webcast about LX9211?
The webcast will provide an in-depth overview of LX9211 for treating diabetic peripheral neuropathic pain.
Who are the featured speakers at the LX9211 event?
Featured speakers include Lexicon leaders and expert panelists from prominent medical institutions.
Will the webcast be available for replay?
Yes, a recording of the webcast will be available on-demand following the live event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LXRX Hedge Fund Activity
We have seen 67 institutional investors add shares of $LXRX stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARTAL GROUP S.A. removed 38,918,903 shares (-22.2%) from their portfolio in Q3 2024, for an estimated $61,102,677
- FMR LLC added 11,179,919 shares (+28.9%) to their portfolio in Q3 2024, for an estimated $17,552,472
- BRAIDWELL LP removed 7,493,366 shares (-90.3%) from their portfolio in Q3 2024, for an estimated $11,764,584
- ORBIMED ADVISORS LLC added 5,177,900 shares (+88.6%) to their portfolio in Q3 2024, for an estimated $8,129,303
- POINT72 ASSET MANAGEMENT, L.P. removed 2,891,141 shares (-70.2%) from their portfolio in Q3 2024, for an estimated $4,539,091
- CITADEL ADVISORS LLC removed 2,310,832 shares (-95.9%) from their portfolio in Q3 2024, for an estimated $3,628,006
- OPALEYE MANAGEMENT INC. removed 1,875,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,943,750
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025.
In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including:
- Mike Exton, PhD, Chief Executive Officer and Director
- Suma Gopinathan, PhD, Vice President, Clinical Development
-
Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer
In addition to presentations by the Lexicon leadership team, the event will include an expert panel and Q&A session on DPNP featuring:
- Rodica Pop-Busui MD, PhD, Jordan Schnitzer Chair in Diabetes | Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health & Science University | 2023 President for Medicine and Science, American Diabetes Association
- Steve Edelman, MD, Professor of Medicine, the Division of Endocrinology, Diabetes & Metabolism at University of California San Diego | Veterans Affairs Medical Center | Founder and Director Taking Control Of Your Diabetes (TCOYD)
Register for the event here . The webcast will be available in the “Events” section of the Lexicon website at https://investors.lexpharma.com/news-events/events and a recording of the webcast will be available following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in cardiology, neuropathic pain, metabolism and other indications. For additional information, please visit
www.lexpharma.com
.
For Investor and Media Inquiries
:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]
